Bioavailability, Safety and Tolerability of Diazepam Nasal Spray Versus Diazepam Rectal Gel (Diastat®)

NCT ID: NCT02474407

Last Updated: 2018-10-16

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

78 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-06-30

Study Completion Date

2016-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a multi-center, open-label, crossover, pharmacokinetic, bio-availability study involving adolescents and adults with refractory (drug-resistant) epilepsy. Cohort 1 comprises the subjects used to determine the relative bioavailability of DZNS versus DRG (Diastat)

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

To determine the bioavailability of diazepam nasal spray versus diazepam rectal gel (Diastat®) under conditions of use in adolescent and adult persons with epilepsy (PWE) meeting the definition of refractory epilepsy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Refractory Epilepsy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

diazepam nasal spray (DZNS)

One dose of diazepam nasal spray is administered as two intranasal sprays; one in each nostril using a nasal spray device.

Group Type EXPERIMENTAL

diazepam nasal spray

Intervention Type DRUG

diazepam rectal gel (DRG)

A single rectal dose of diazepam will be administered to subjects according to the Diastat prescribing information.

Group Type ACTIVE_COMPARATOR

diazepam rectal gel

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

diazepam nasal spray

Intervention Type DRUG

diazepam rectal gel

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Diazepam Diastat® AcuDial™

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of refractory epilepsy
* Body weight 26 to 111 kilogram (kg) inclusive

Exclusion Criteria

* Male or female subject who is not surgically sterile or female subject who is less than 2 years postmenopausal, and does not agree to use a highly effective birth control method during the study and up to 3 months after the last dose of investigational product
* Female subject who is pregnant, breastfeeding, or planning to become pregnant
* Presence or history of any abnormality or illness that may affect the absorption, distribution, metabolism or elimination of diazepam
Minimum Eligible Age

12 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Acorda Therapeutics

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Lee Min Jae

Role: STUDY_DIRECTOR

SK Biopharmaceuticals Co, Ltd

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Acorda Site #115

Little Rock, Arkansas, United States

Site Status

Acorda Site #127

Washington D.C., District of Columbia, United States

Site Status

Acorda Site #101

Tampa, Florida, United States

Site Status

Acorda Site #125

Honolulu, Hawaii, United States

Site Status

Acorda Site #104

Lexington, Kentucky, United States

Site Status

Acorda Site #111

Baltimore, Maryland, United States

Site Status

Acorda Site #102

Bethesda, Maryland, United States

Site Status

Acorda Site #110

Ann Arbor, Michigan, United States

Site Status

Acorda Site #117

Jackson, Mississippi, United States

Site Status

Acorda Site #112

St Louis, Missouri, United States

Site Status

Acorda Site #128

Edison, New Jersey, United States

Site Status

Acorda Site #121

Hackensack, New Jersey, United States

Site Status

Acorda Site #123

Amherst, New York, United States

Site Status

Acorda Site #119

Rochester, New York, United States

Site Status

Acorda Site #132

Chapel Hill, North Carolina, United States

Site Status

Acorda Site #114

Portland, Oregon, United States

Site Status

Acorda Site #116

Philadelphia, Pennsylvania, United States

Site Status

Acorda Site #105

Philadelphia, Pennsylvania, United States

Site Status

Acorda Site #130

Memphis, Tennessee, United States

Site Status

Acorda Site #103

Bellaire, Texas, United States

Site Status

Acorda Site #122

Dallas, Texas, United States

Site Status

Acorda Site #108

Houston, Texas, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

DZNS-EP-1019

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Effects of Diazepam on RNS Detections
NCT05273398 COMPLETED PHASE4
Study of Midazolam in Healthy Adults
NCT04679623 COMPLETED PHASE1